Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Certain Aussie Home-Use IVDs Subject To Full Safety Evaluation – TGA

This article was originally published in The Gray Sheet

Executive Summary

Sponsors of home-use in vitro diagnostics intended for the identification or monitoring of serious conditions will need to demonstrate that lay users are able to obtain comparable results to trained professionals, according to recently-released draft guidelines issued by Australia's Therapeutics Goods Administration

You may also be interested in...



SUD Reprocessing, Tissue Regulation Addressed By Australia’s TGA

Device manufacturers will have a two-year phase-in period to comply with new 1single-use device reprocessing regulatory requirements proposed by Australia's Therapeutic Goods Administration

SUD Reprocessing, Tissue Regulation Addressed By Australia’s TGA

Device manufacturers will have a two-year phase-in period to comply with new 1single-use device reprocessing regulatory requirements proposed by Australia's Therapeutic Goods Administration

Australian IVD Framework Proposal Would Broaden Regulatory Oversight

Australia's proposed regulatory structure for in vitro diagnostic devices would bring new regulatory requirements and costs for a number of products that currently are exempt from oversight

Latest Headlines
See All
UsernamePublicRestriction

Register

MT018762

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel